The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
Open accessAbstract
The 4-1BB receptor is an inducible type I membrane protein and member of the tumor necrosis factor receptor (TNFR) superfamily that is rapidly expressed on the surface of CD4+ and CD8+ T cells after antigen- or mitogen-induced activation. Cross-linking of 4-1BB and the T cell receptor (TCR) on activated T cells has been shown to deliver a costimulatory signal to T cells. Here, we expand upon previously published studies by demonstrating that CD8+ T cells when compared with CD4+ T cells are preferentially responsive to both early activation events and proliferative signals provided via the TCR and 4-1BB. In comparison, CD28-mediated costimulatory signals appear to function in a reciprocal manner to those induced through 4-1BB costimulation. In vivo examination of the effects of anti-4-1BB monoclonal antibodies (mAbs) on antigen-induced T cell activation have shown that the administration of epitope-specific anti-4-1BB mAbs amplified the generation of H-2d–specific cytotoxic T cells in a murine model of acute graft versus host disease (GVHD) and enhanced the rapidity of cardiac allograft or skin transplant rejection in mice. Cytokine analysis of in vitro activated CD4+ and CD8+ T cells revealed that anti-4-1BB costimulation markedly enhanced interferon-γ production by CD8+ T cells and that anti-4-1BB mediated proliferation of CD8+ T cells appears to be IL-2 independent. The results of these studies suggest that regulatory signals delivered by the 4-1BB receptor play an important role in the regulation of cytotoxic T cells in cellular immune responses to antigen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
Kearney, J. F., Radbruch, A., Liesegang, B., & Rajewsky, K. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.123.4.1548 · Cited by 1,852
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Larsen, C. P., Elwood, E. T., Alexander, D. Z., Ritchie, S. C., Hendrix, R., Tucker-Burden, C., Cho, H. R., Aruffo, A., Hollenbaugh, D., Linsley, P. S., et al. (1996) · Nature · doi:10.1038/381434a0 · Cited by 1,455
Self-citationInducible T cell antigen 4-1BB. Analysis of expression and function
Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T., & Kwon, B. S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.3.771 · Cited by 421
Goodwin, R. G., Din, W. S., Davis‐Smith, T., Anderson, D. M., Gimpel, S. D., Sato, T. A., Maliszewski, C. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., et al. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231037 · Cited by 334
Moslecular and biological characterization of human 4‐1BB and its ligands
Alderson, M. R., Smith, C. A., Tough, T. W., Davis‐Smith, T., Armitage, R. J., Falk, B., Roux, E., Baker, E., Sutherland, G. R., Din, W. S., et al. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240943 · Cited by 244
Pollok, K. E., Kim, Y., Hurtado, J., Zhou, Z., Kim, K. K., & Kwon, B. S. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240215 · Cited by 218
ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages
Schwarz, H., Valbracht, J., Tuckwell, J., von Kempis, J., & Lotz, M. (1995) · Blood · doi:10.1182/blood.v85.4.1043.bloodjournal8541043 · Cited by 141
Lane, R. D. (1985) · Journal of Immunological Methods · doi:10.1016/0022-1759(85)90207-8 · Cited by 139
T-cell activation molecule 4-1BB binds to extracellular matrix proteins.
Chalupny, N. J., Peach, R., Hollenbaugh, D. L., Ledbetter, J. A., Farr, A. G., & Aruffo, A. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10360 · Cited by 58
Self-citation
Cited by
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Dynamics of T Lymphocyte Responses: Intermediates, Effectors, and Memory Cells
Lanzavecchia, A., & Sallusto, F. (2000) · Science · doi:10.1126/science.290.5489.92 · Cited by 796
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Arch, R. H., Gedrich, R. W., & Thompson, C. B. (1998) · Genes & Development · doi:10.1101/gad.12.18.2821 · Cited by 608
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses
Gramaglia, I., Weinberg, A. D., Lemon, M., & Croft, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6510 · Cited by 527
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Engineering and Design of Chimeric Antigen Receptors
Guedan, S., Calderon, H., Posey, A. D., & Maus, M. V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 453
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
Kochenderfer, J. N., Feldman, S. A., Zhao, Y., Xu, H., Black, M. A., Morgan, R. A., Wilson, W. H., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ac6138 · Cited by 408
Tamada, K., Shimozaki, K., Chapoval, A. I., Zhai, Y., Su, J., Chen, S.-F., Hsieh, S.-L., Nagata, S., Ni, J., & Chen, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4105 · Cited by 391
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
Self-citationCostimulatory regulation of T cell function
Chambers, C. A., & Allison, J. P. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80027-1 · Cited by 377
Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S., & Chen, L. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1396 · Cited by 363
Self-citationTrambley, J., Bingaman, A. W., Lin, A., Elwood, E. T., Waitze, S.-Y., Ha, J., Durham, M. M., Corbascio, M., Cowan, S. R., Pearson, T. C., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8082 · Cited by 356
Self-citationCannons, J. L., Lau, P., Ghumman, B., DeBenedette, M. A., Yagita, H., Okumura, K., & Watts, T. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1313 · Cited by 355
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Araki, Y., Wang, Z., Zang, C., Wood, W. H., Schones, D., Cui, K., Roh, T.-Y., Lhotsky, B., Wersto, R. P., Peng, W., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.006 · Cited by 328
4-1BB-mediated immunotherapy of rheumatoid arthritis
Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K., Vinay, D. S., & Kwon, B. S. (2004) · Nature Medicine · doi:10.1038/nm1107 · Cited by 325
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenedette, M. A., Mak, T. W., Choi, Y., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1849 · Cited by 322
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Ye, Q., Song, D.-G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G., & Powell, D. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0945 · Cited by 322
Kopf, M., Ruedl, C., Schmitz, N., Gallimore, A., Lefrang, K., Ecabert, B., Odermatt, B., & Bachmann, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80144-2 · Cited by 321
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Self-citationImmune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Wang, C., Lin, G. H. Y., McPherson, A. J., & Watts, T. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00765.x · Cited by 298
Lymph Node Genesis Is Induced by Signaling through the Lymphotoxin β Receptor
Rennert, P. D., James, D., Mackay, F., Browning, J. L., & Hochman, P. S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80589-0 · Cited by 297
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells
Futagawa, T., Akiba, H., Kodama, T., Takeda, K., Hosoda, Y., Yagita, H., & Okumura, K. (2002) · International Immunology · doi:10.1093/intimm/14.3.275 · Cited by 283
DeBenedette, M. A., Wen, T., Bachmann, M. F., Ohashi, P. S., Barber, B. H., Stocking, K. L., Peschon, J. J., & Watts, T. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4833 · Cited by 282
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
Shires, J., Theodoridis, E., & Hayday, A. C. (2001) · Immunity · doi:10.1016/s1074-7613(01)00192-3 · Cited by 276
Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., Hüsser, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5989 · Cited by 270
Bertram, E. M., Lau, P., & Watts, T. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3777 · Cited by 265
Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C., & Larsen, C. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4859 · Cited by 259
Self-citationWilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
Weinberg, A. D., Wegmann, K. W., Funatake, C., & Whitham, R. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1818 · Cited by 252
Zhang, W., Jordan, K. R., Schulte, B., & Purev, E. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s175113 · Cited by 60
Wells, J. W., Cowled, C. J., Farzaneh, F., & Noble, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3422 · Cited by 53
Potential importance of B cells in aging and aging-associated neurodegenerative diseases
Biragyn, A., Aliseychik, M., & Rogaev, E. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0615-8 · Cited by 25
Metadata
- Authors
- Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., Pearson, T. C., Ledbetter, J. A., Aruffo, A., & Mittler, R. S.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1997-07-07
- Volume
- 186
- Issue
- 1
- Pages
- 47-55
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2099241614
- Cited by
- 804
- References
- 10
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.